RECURSION PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Increase Decrease In Operating Lease Liability of -$6.42 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2024-08-08
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$2.62M.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$3.79M.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2023-12-31 was -$1.91M.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2023-09-30 was -$2.51M.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$9.86M.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was -$7.11M.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2021 was $0.00.
- RECURSION PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2020 was $0.00.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.42M 10-Q · filed 2024-08-08 | -$8.33M derived: sum of 3 quarters · filed 2024-08-08 | -$10.84M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | -$3.79M 10-Q · filed 2024-05-09 | -$5.71M derived: sum of 2 quarters · filed 2024-05-09 | -$8.21M derived: sum of 3 quarters · filed 2024-05-09 | -$11.21M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$4.42M derived: sum of 2 quarters · filed 2024-02-29 | -$7.42M derived: sum of 3 quarters · filed 2024-08-08 | -$9.86M 10-K · filed 2024-02-29 |
| 2023-09-30 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$5.51M derived: sum of 2 quarters · filed 2024-08-08 | -$7.95M 10-Q · filed 2023-11-09 | -$10.13M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.44M 10-Q · filed 2024-08-08 | -$7.63M derived: sum of 3 quarters · filed 2024-08-08 | -$9.74M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$2.44M 10-Q · filed 2024-05-09 | -$4.63M derived: sum of 2 quarters · filed 2024-05-09 | -$6.74M derived: sum of 3 quarters · filed 2024-05-09 | -$8.29M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$4.30M derived: sum of 2 quarters · filed 2024-02-29 | -$5.84M derived: sum of 3 quarters · filed 2024-02-29 | -$7.11M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.66M derived: sum of 2 quarters · filed 2023-11-09 | -$4.93M 10-Q · filed 2023-11-09 | -$4.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.81M 10-Q · filed 2023-08-08 | -$2.81M derived: sum of 3 quarters · filed 2024-02-29 | -$2.81M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$1.26M 10-Q · filed 2023-05-08 | -$1.26M derived: sum of 2 quarters · filed 2024-02-29 | -$1.26M derived: sum of 3 quarters · filed 2024-02-29 | -$1.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |